Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 580 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Your questions on our research strategy March 29, 2022 “Mi corazón siempre dolerá”: Cómo honro a mi mejor amiga de... April 26, 2022 EMA Recommends Approval of the Marketing Authorisation for Tagraxofusp November 24, 2020 ΚΑΡΚΙΝΟΣ ΤΟΥ ΜΑΣΤΟΥ February 10, 2019 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΡΟΣΤΑΤΗ Efficacy of Dabrafenib Plus Trametinib in First-Line Treatment for Children and... Making Cancer Care More Equitable: A Cancer Survivor’s Story Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery
